PDS01ADC

Phase 2Small molecule

NNational Cancer Institute (NCI)

PDS01ADC is one of 25 small molecule programs targeting Cancer Of Prostate. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of ProstateRecruiting

Oropharyngeal CancerActive, not recruiting

Kaposi SarcomaRecruiting

Cancer of ProstatePhase 2

Recruiting

Oropharyngeal CancerPreclinical

Active, not recruiting

Kaposi SarcomaPreclinical

Recruiting

Competition

Competitive Landscape

19 competitors in Oropharyngeal Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

10 2

Imfinzi

AstraZeneca

Phase 3

1 3

Taxol

Teva

Phase 2

3 4

Beyfortus

BeiGene

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

4 6

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

1 7

Fludara

Sanofi

Phase 1

1 8

Balstilimab

AAgenus Inc.

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 10

PDS01ADC

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Cancer of Prostate

NCT04633252

Q4 2027

Phase 2Recruiting

Cancer of Prostate

NCT05361798

Q4 2028

PreclinicalRecruiting

Kaposi Sarcoma

NCT04303117

Phase 1Active, not recruiting

Urothelial Cancer

NCT04235777

Phase 2Recruiting

Metastatic Colorectal Cancer (mcrc)

NCT05286814

Q4 2029

Phase 2Recruiting

Prostate Cancer

NCT06096870

Clinical

Trials by Indication[1]

Cancer Of Prostate2 trials

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04633252·86 enrolled

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05361798·65 enrolled

Metastatic Colorectal Cancer (mCRC)1 trial

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05286814·70 enrolled

Kaposi Sarcoma1 trial

Phase I/II Study of PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04303117·80 enrolled

Prostate Cancer1 trial

Phase II Trial of Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06096870·65 enrolled

Urothelial Cancer1 trial

A Phase I Study of Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04235777·22 enrolled

1 more indication

Oropharyngeal Cancer1 trial

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT04708470·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PDS01ADC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PDS01ADC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PDS01ADC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

PDS01ADC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Q4 2029

Trials by Indication[1]

Cancer Of Prostate2 trials

Metastatic Colorectal Cancer (mCRC)1 trial

Kaposi Sarcoma1 trial

Prostate Cancer1 trial

Urothelial Cancer1 trial

Oropharyngeal Cancer1 trial

References

Drug Info

Quick Facts

Related News